CHIR-124 (CHIR124; CHIR 124) is a novel, potent and selective quinolone-based small molecule Chk1 (Checkpoint kinase1) inhibitor with potential anticancer activity.

CCT-244747 is a novel, potent, highly selective and orally bioavailable ATP-competitive CHK1 inhibitor (IC50 = 7.7 nM) with potential anticancer activity. CCT244747 inhibited cellular CHK1 activity (IC(50) 29-170 nmol/L), significantly enhanced the cytotoxicity of several anticancer drugs, and abrogated drug-induced S and G(2) arrest in multiple tumor cell lines. CCT244747 represents the first structural disclosure […]

Rabusertib (also known as IC-83; LY-2603618; LY 2603618; IC83) is a novel, potent and selective Chk1 (cell cycle checkpoint kinase 2) inhibitor with potential antitumor activity.

MK-8776 (also known as SCH900776; MK8776; SCH-900776; MK 8776) is a novel, highly potent and selective Chk1 (cell cycle checkpoint kinase 1) inhibitor with potential antineoplastic, radiosensitization and chemosensitization activities.

CCT245737 (CCT-245737) is a novel, potent, orally bioavailable and selective ATP-competitive inhibitor of CHK1 (checkpoint kinase 1) with anticancer activity.

Chk2 Inhibitor II (also known as BML-277) is an ATP-competitive inhibitor of Chk2 (checkpoint kinase 2) with an IC50 of 15 nM.

SCH900776 S-isomer is the S-isomer of SCH900776 (MK-8776), which is a novel, highly potent and selective Chk1 (cell cycle checkpoint kinase 1) inhibitor with IC50 of 3 nM in a cell-free assay.

GDC-0575 (also called ARRY-575, RG7741) is a novel, potent and selective inhibitor of CHK1 (Check point kinases) which specifically binds to and inhibits CHK1 with an IC50 of 1.2 nM.

CCT241533 HCl, the dihydrochloride salt of CCT-241533, is a novel, potent and selective CHK2 inhibitor with anticancer activity.

PF-477736 (also known as PF-736; PF-00477736; PF477736) is a novel, selective, potent and ATP-competitive Chk1 inhibitor with potential antitumor activity.